Opendata, web and dolomites

FAIRplus SIGNED

FAIRplus

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "FAIRplus" data sheet

The following table provides information about the project.

Coordinator
EUROPEAN MOLECULAR BIOLOGY LABORATORY 

Organization address
address: Meyerhofstrasse 1
city: HEIDELBERG
postcode: 69117
website: http://www.embl.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 8˙228˙650 €
 EC max contribution 3˙996˙150 € (49%)
 Programme 1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
 Code Call H2020-JTI-IMI2-2017-12-two-stage
 Funding Scheme IMI2-RIA
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2022-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    EUROPEAN MOLECULAR BIOLOGY LABORATORY DE (HEIDELBERG) coordinator 855˙638.00
2    FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V. DE (MUNCHEN) participant 326˙162.00
3    THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD UK (OXFORD) participant 304˙825.00
4    STICHTING LYGATURE NL (UTRECHT) participant 296˙511.00
5    UNIVERSITE DU LUXEMBOURG LU (ESCH-SUR-ALZETTE) participant 294˙037.00
6    THE UNIVERSITY OF MANCHESTER UK (MANCHESTER) participant 281˙417.00
7    UNIVERSITEIT MAASTRICHT NL (MAASTRICHT) participant 258˙401.00
8    IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE UK (LONDON) participant 235˙255.00
9    OPEN PHACTS FOUNDATION LBG UK (CAMBRIDGE) participant 211˙937.00
10    THE HYVE BV NL (UTRECHT) participant 209˙435.00
11    SIB INSTITUT SUISSE DE BIOINFORMATIQUE CH (GENEVE) participant 191˙837.00
12    BARCELONA SUPERCOMPUTING CENTER - CENTRO NACIONAL DE SUPERCOMPUTACION ES (BARCELONA) participant 190˙306.00
13    FUNDACIO INSTITUT MAR D INVESTIGACIONS MEDIQUES IMIM ES (BARCELONA) participant 162˙383.00
14    UNIVERSITE PAUL SABATIER TOULOUSE III FR (TOULOUSE CEDEX 9) participant 107˙513.00
15    HERIOT-WATT UNIVERSITY UK (EDINBURGH) participant 70˙487.00
16    ASTRAZENECA AB SE (SODERTAELJE) participant 0.00
17    BAYER AKTIENGESELLSCHAFT DE (Leverkusen) participant 0.00
18    BOEHRINGER INGELHEIM INTERNATIONALGMBH DE (INGELHEIM) participant 0.00
19    Eli Lilly and Company Limited UK (Basingstoke) participant 0.00
20    GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD. UK (BRENTFORD) participant 0.00
21    JANSSEN PHARMACEUTICA NV BE (BEERSE) participant 0.00
22    NOVARTIS PHARMA AG CH (BASEL) participant 0.00

Map

 Project objective

Wide sharing of knowledge and data drives the progression of science. Shared data allows other researchers to reproduce findings and benchmark quality of experiments. Sharing data so that other researchers can Find, Access and Interoperate – i.e. integrate the data with the outcomes of their own experiments - allows Reuse and an opportunity to build the large aggregated cohorts we need to detect rare signals and manage the many confounding factors in translational research. This project will develop the guidelines and tools needed to make data FAIR. Through worked examples using IMI and EFPIA data and application and extension of existing methods we will improve the level of discovery, accessibility, interoperability and reusability of selected IMI and EFPIA data. In addition, through disseminated guidelines and tailored training for data handlers in academia, SMEs and pharmaceuticals, data management culture will change and be sustained and datasets will be reused by pharmaceutical companies, academia and SMEs. Our FAIR SME & Innovation programme will enable wide data reuse and foster an innovation ecosystem around these data that power future re-use, knowledge generation, and societal benefit. We call this approach ‘FAIRplus’.

 Deliverables

List of deliverables.
D1.1 First 3 data sets from Pilot selected and available Documents, reports 2020-04-25 10:39:11
D5.1 Website, project governance and communication assets and guidelines available Documents, reports 2020-04-25 10:39:11
D4.1 Description of the objective evaluation criteria for the application review Documents, reports 2020-04-25 10:39:11

Take a look to the deliverables list in detail:  detailed list of FAIRplus deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "FAIRPLUS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "FAIRPLUS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

AB-DiRecT (2019)

Antibiotic Distribution and Recovery in Tissue

Read More  

EBOVAC3 (2018)

Bringing a prophylactic Ebola vaccine to licensure

Read More  

RespiriTB (2019)

Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors

Read More